BioCentury | Oct 24, 2020
Emerging Company Profile

SparingVision’s line of sight to a mutation-agnostic gene therapy for ophthalmic disease

...of retinal degeneration, with RdCVF providing a metabolic...
BioCentury | Oct 19, 2020
Finance

How Nimbus’ focus on internal pipeline could point to long-awaited exit

With a new $60 million crossover round and an internal pipeline moving through the clinic, computational chemistry company Nimbus may be nearing a liquidity event for investors who have stuck with the...
BioCentury | Oct 17, 2020
Emerging Company Profile

Fed Bio: designing gut microbiomes with staying power and enhancing immune-modulating bacteria

...University, Chan Zuckerberg Biohub and in-houseDisease focus: Endocrine/metabolic...
...Seventure PartnersCEO: Emily Drabant ConleyPatents: Undisclosed Sandi Wong Federation Bio Endocrine/Metabolic Hyperoxaluria microbiome...
BioCentury | Oct 17, 2020
Product Development

How the PanCAN master protocol could promote innovation in pancreatic cancer

The motivation for launching the first adaptive platform trial in pancreatic cancer is to stimulate therapeutic innovation in an indication sorely in need of new ideas. The hope of the non-profit...
BioCentury | Oct 13, 2020
Product Development

Data Bytes: coronavirus-targeted small molecules

...with undisclosed targets, four are categorized as antivirals, two as immunosuppresants, and one as a metabolic...
BioCentury | Oct 8, 2020
Product Development

Mapping opportunities for China’s early cancer detection boom

...of Berry Genomics Co. Ltd. (SZSE:000710), which markets NIPTs for chromosomal abnormalities and genetic tests for metabolic...
BioCentury | Oct 6, 2020
Deals

Oct. 5 Quick Takes: BridgeBio reacquiring Eidos, Amgen KRAS data, after-hours tumbles for Iovance, Y-mAbs and more

BridgeBio reacquiring Eidos spinoutFour years after spinning out Eidos Therapeutics Inc. (NASDAQ:EIDX), BridgeBio Pharma Inc. (NASDAQ:BBIO) will acquire the 36.3% of that company it does not already own. Eidos’ lead program acoramidis (AG-10) is in...
BioCentury | Oct 2, 2020
Distillery Therapeutics

Blocking an L-phenylalanine and L-arginine metabolic enzyme for cancer

DISEASE CATEGORY: Cancer INDICATION: Brain cancer; chronic lymphocytic leukemia (CLL) Inhibiting IL4I1, which metabolizes L-phenylalanine and L-arginine, could treat CLL, glioblastoma multiforme and glioma. Computational analyses of gene expression data and published studies identified a pan-tissue...
BioCentury | Oct 1, 2020
Product Development

Sept. 30 Quick Takes: $234M for NIH’s RADx-UP; plus CureVac, Allena, Covaxx

...Finance will extend the cash runway of Allena Pharmaceuticals Inc. (NASDAQ:ALNA) into 4Q21. The rare metabolic...
BioCentury | Sep 30, 2020
Distillery Therapeutics

An FGF21, GLP-1 fusion protein for diabetes, obesity

...2020doi:10.1126/sciadv.aaz9890CONTACT: Ashutosh Chilkoti, Duke University, Durham, N.C.email: chilkoti@duke.edu Claire Quang Duke University Glucagon-like peptide-1 (GLP-1) Fibroblast growth factor 21 (FGF21) Endocrine/Metabolic Obesity Diabetes...
Items per page:
1 - 10 of 27647
BioCentury | Oct 24, 2020
Emerging Company Profile

SparingVision’s line of sight to a mutation-agnostic gene therapy for ophthalmic disease

...of retinal degeneration, with RdCVF providing a metabolic...
BioCentury | Oct 19, 2020
Finance

How Nimbus’ focus on internal pipeline could point to long-awaited exit

With a new $60 million crossover round and an internal pipeline moving through the clinic, computational chemistry company Nimbus may be nearing a liquidity event for investors who have stuck with the...
BioCentury | Oct 17, 2020
Emerging Company Profile

Fed Bio: designing gut microbiomes with staying power and enhancing immune-modulating bacteria

...University, Chan Zuckerberg Biohub and in-houseDisease focus: Endocrine/metabolic...
...Seventure PartnersCEO: Emily Drabant ConleyPatents: Undisclosed Sandi Wong Federation Bio Endocrine/Metabolic Hyperoxaluria microbiome...
BioCentury | Oct 17, 2020
Product Development

How the PanCAN master protocol could promote innovation in pancreatic cancer

The motivation for launching the first adaptive platform trial in pancreatic cancer is to stimulate therapeutic innovation in an indication sorely in need of new ideas. The hope of the non-profit...
BioCentury | Oct 13, 2020
Product Development

Data Bytes: coronavirus-targeted small molecules

...with undisclosed targets, four are categorized as antivirals, two as immunosuppresants, and one as a metabolic...
BioCentury | Oct 8, 2020
Product Development

Mapping opportunities for China’s early cancer detection boom

...of Berry Genomics Co. Ltd. (SZSE:000710), which markets NIPTs for chromosomal abnormalities and genetic tests for metabolic...
BioCentury | Oct 6, 2020
Deals

Oct. 5 Quick Takes: BridgeBio reacquiring Eidos, Amgen KRAS data, after-hours tumbles for Iovance, Y-mAbs and more

BridgeBio reacquiring Eidos spinoutFour years after spinning out Eidos Therapeutics Inc. (NASDAQ:EIDX), BridgeBio Pharma Inc. (NASDAQ:BBIO) will acquire the 36.3% of that company it does not already own. Eidos’ lead program acoramidis (AG-10) is in...
BioCentury | Oct 2, 2020
Distillery Therapeutics

Blocking an L-phenylalanine and L-arginine metabolic enzyme for cancer

DISEASE CATEGORY: Cancer INDICATION: Brain cancer; chronic lymphocytic leukemia (CLL) Inhibiting IL4I1, which metabolizes L-phenylalanine and L-arginine, could treat CLL, glioblastoma multiforme and glioma. Computational analyses of gene expression data and published studies identified a pan-tissue...
BioCentury | Oct 1, 2020
Product Development

Sept. 30 Quick Takes: $234M for NIH’s RADx-UP; plus CureVac, Allena, Covaxx

...Finance will extend the cash runway of Allena Pharmaceuticals Inc. (NASDAQ:ALNA) into 4Q21. The rare metabolic...
BioCentury | Sep 30, 2020
Distillery Therapeutics

An FGF21, GLP-1 fusion protein for diabetes, obesity

...2020doi:10.1126/sciadv.aaz9890CONTACT: Ashutosh Chilkoti, Duke University, Durham, N.C.email: chilkoti@duke.edu Claire Quang Duke University Glucagon-like peptide-1 (GLP-1) Fibroblast growth factor 21 (FGF21) Endocrine/Metabolic Obesity Diabetes...
Items per page:
1 - 10 of 27647